Antianginal effectiveness and tolerability of ivabradine in patients with stable angina: CONTROL-2 Study results

• Main Authors: Yu. A. Karpov, M. G. Glezer, Yu. A. Vasyuk, R. T. Saygitov, E. L. Shkolnik
• Format: Article
• Language: Russian
• Published: «SILICEA-POLIGRAF» LLC 1970-01-01
• Series: Кардиоваскулярная терапия и профилактика
• Subjects: stable angina; treatment; β-adrenoblockers; quality of life; ivabradine
• Online Access: https://cardiovascular.elpub.ru/jour/article/view/2069
• ISSN: 1728-8800; 2619-0125

Aim. To compare the effectiveness of the combination therapy with ivabradine and β-adrenoblockers (β-AB) and the dose-titration β-AB therapy. Material and methods. This multi-centre, open, controlled study included 1104 patients with functional Class (FC) II-III stable angina (SA), sinus rhythm, and heart rate (HR) ≥60 bpm, who received regular β-AB therapy in submaximal doses. The participants were divided into the standard therapy group (β-AB therapy with the dose titration to the maximal tolerated dose; 228 patients (20,7%)) and the ivabradine therapy group (876 patients (79,3%))Results. Both groups were comparable by main demographical and clinical characteristics. Adding ivabradine to the β-AB therapy resulted in a more pronounced HR reduction at Week 16, compared to the standard therapy group (61±6 vs. 63±8 bpm; p=0,001). By the end of the study, the percentage of the patients with FC I SA was significantly higher in the ivabradine group than in the standard therapy group (37,1% vs. 28%; p=0,017). The average number of angina attacks between Weeks 8 and 16 was significantly lower in the ivabradine group than in the standard therapy group – 4 (2;10) vs. 6 (2;15), respectively (p=0,015). In the standard therapy group, the incidence of adverse events, such as dyspnoea, hypotension, and fatigue, was significantly higher than in the ivabradine group – 18,4% vs. 9,4%, respectively (p<0,001). Conclusion. In SA patients, the combination therapy with β-AB and ivabradine demonstrated good tolerability, safety, and high antianginal effectiveness, which resulted in a more pronounced clinical improvement, compared to the dose-titration β-AB therapy.